10.13.15
Biosense Webster Inc. has launched its Confidense Module, a technology that streamlines the creation of real-time three-dimensional (3-D) maps of a patient’s cardiac structures during catheter ablation procedures.
Using an advanced, proprietary algorithm, the Confidense Module enhances the process for validating information, or “points,” acquired during multi-electrode mapping, enabling electrophysiologists to focus their time and expertise on the most relevant data during the mapping process, company executives said in a news release.
“While high-density maps generated through multi-electrode mapping provide the most comprehensive and accurate image of the cardiac structures, this process can prove to be time intensive,” said Vias Markides, M.D., director of the Heart Division at Royal Brompton Hospital in London, United Kingdom. “The new Confidense Module streamlines the mapping and validation process, which has the potential to reduce overall mapping, annotation and re-annotation time. I’m pleased that continued innovation in this space is enabling us to realize important clinical efficiencies while preserving the critical data and accuracy we have come to rely on from the CARTO System.”
Multi-electrode mapping allows for the rapid acquisition of a large quantity of data used to generate detailed, high-density maps on the CARTO 3 System. Previously, validating the information acquired through multi-electrode mapping required a very detailed manual process but the Confidense Module enhances the 3-D mapping experience with several features that simplify and accelerate map creation while maintaining accuracy, bigwigs claimed in a news release. The module also provides a real-time assessment of whether catheter electrodes are close to heart tissue while selectively using the points closest to the tissue to generate a high-quality 3-D map; enhances the consistency of quality data acquisition with an advanced algorithm; and accurately identifies and quickly evaluates points whose timing is judged to be inconsistent in comparison with neighboring points, which then are flagged and immediately brought to the doctor’s attention.
“We are collaborating closely with the clinical community to introduce innovations that not only enable access to the most accurate and comprehensive mapping data available, but in making the acquisition of this data fast, simpler and more intuitive for users,” said David Shepherd, U.S. president for Biosense Webster. “We are excited to introduce this innovation for our foundational CARTO System platform, a fully integrated system.”
The Confidense Module is CE Marked in Europe and received 510(k) clearance in the United States.
The CARTO 3 System is an advanced imaging technology that utilizes electromagnetic technology to create real-time 3-D maps of a patient’s cardiac structures. The system is designed to help electrophysiologists navigate the heart by generating an accurate 3-D map, as well as pinpointing the exact location and orientation of catheters in the heart during catheter ablation procedures for patients suffering from heart rhythm conditions (cardiac arrhythmias). During catheter ablation, doctors insert a therapeutic catheter through a small incision in the groin where it is then weaved up to the heart through a blood vessel. Once it reaches the left upper chamber of the heart (atrium), radiofrequency energy is delivered to the heart wall to create lesions that block faulty electrical impulses that can cause heart rhythm disorders.
Biosense Webster develops diagnostic and treatment technologies for heart rhythm disorders. The Diamond Bar, Calif.-based company is part of Johnson & Johnson.
Using an advanced, proprietary algorithm, the Confidense Module enhances the process for validating information, or “points,” acquired during multi-electrode mapping, enabling electrophysiologists to focus their time and expertise on the most relevant data during the mapping process, company executives said in a news release.
“While high-density maps generated through multi-electrode mapping provide the most comprehensive and accurate image of the cardiac structures, this process can prove to be time intensive,” said Vias Markides, M.D., director of the Heart Division at Royal Brompton Hospital in London, United Kingdom. “The new Confidense Module streamlines the mapping and validation process, which has the potential to reduce overall mapping, annotation and re-annotation time. I’m pleased that continued innovation in this space is enabling us to realize important clinical efficiencies while preserving the critical data and accuracy we have come to rely on from the CARTO System.”
Multi-electrode mapping allows for the rapid acquisition of a large quantity of data used to generate detailed, high-density maps on the CARTO 3 System. Previously, validating the information acquired through multi-electrode mapping required a very detailed manual process but the Confidense Module enhances the 3-D mapping experience with several features that simplify and accelerate map creation while maintaining accuracy, bigwigs claimed in a news release. The module also provides a real-time assessment of whether catheter electrodes are close to heart tissue while selectively using the points closest to the tissue to generate a high-quality 3-D map; enhances the consistency of quality data acquisition with an advanced algorithm; and accurately identifies and quickly evaluates points whose timing is judged to be inconsistent in comparison with neighboring points, which then are flagged and immediately brought to the doctor’s attention.
“We are collaborating closely with the clinical community to introduce innovations that not only enable access to the most accurate and comprehensive mapping data available, but in making the acquisition of this data fast, simpler and more intuitive for users,” said David Shepherd, U.S. president for Biosense Webster. “We are excited to introduce this innovation for our foundational CARTO System platform, a fully integrated system.”
The Confidense Module is CE Marked in Europe and received 510(k) clearance in the United States.
The CARTO 3 System is an advanced imaging technology that utilizes electromagnetic technology to create real-time 3-D maps of a patient’s cardiac structures. The system is designed to help electrophysiologists navigate the heart by generating an accurate 3-D map, as well as pinpointing the exact location and orientation of catheters in the heart during catheter ablation procedures for patients suffering from heart rhythm conditions (cardiac arrhythmias). During catheter ablation, doctors insert a therapeutic catheter through a small incision in the groin where it is then weaved up to the heart through a blood vessel. Once it reaches the left upper chamber of the heart (atrium), radiofrequency energy is delivered to the heart wall to create lesions that block faulty electrical impulses that can cause heart rhythm disorders.
Biosense Webster develops diagnostic and treatment technologies for heart rhythm disorders. The Diamond Bar, Calif.-based company is part of Johnson & Johnson.